Jama Pitman - 28 Oct 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role: Title: SVP, Regulatory, Quality, & Portfolio Management
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 28 Oct 2023
Net transactions value: -$16,909
Form type: 4
Filing time: 31 Oct 2023, 16:10:50 UTC
Previous filing: 21 Jun 2023
Next filing: 14 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award		+5,576	+13%		49,690	28 Oct 2023	Direct	F1, F2
transaction	DCPH	Common Stock	Sale	$16,909	-1,407	-2.8%	$12.02	48,283	30 Oct 2023	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 5,576 RSUs.
F2	Includes 302 shares previously acquired under the Issuer's 2017 Employee Stock Purchase Plan.
F3	This sale was to cover tax liabilities in the vesting of RSUs.

Remarks:

Title: SVP, Regulatory, Quality, & Portfolio Management